BioXcel Therapeutics, Inc.
BTAI • NASDAQ
BioXcel Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Vimal D. Mehta, with a market cap of $30.7M.
CEOVimal D. Mehta
Next Earnings
Upcoming earnings announcement for BioXcel Therapeutics, Inc.
Date
Monday, May 11, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.61
Revenue Estimate
$280.0K
Earnings History
Past 12 earnings reports for BioXcel Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 2026 | Q4 2025 | -$0.58Est: -$0.52 | -11.5% | $256.0KEst: $142.9K | +79.1% |  10-K |
| Nov 12, 2025 | Q3 2025 | -$2.18Est: -$1.42 | -53.5% | $98.0KEst: $190.0K | -48.4% | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$2.45Est: -$1.86 | -31.7% | $120.0KEst: $227.5K | -47.3% | 10-Q |
| May 12, 2025 | Q1 2025 | -$1.50Est: -$3.04 | +50.7% | $168.0KEst: $350.0K | -52.0% | 10-Q |
| Mar 27, 2025 | Q4 2024 | -$3.57Est: -$4.96 | +28.0% | $366.0KEst: $413.8K | -11.6% | 10-K |
| Nov 14, 2024 | Q3 2024 | -$5.12Est: -$7.68 | +33.3% | $214.0KEst: $1.3M | -83.9% | 10-Q |
| Aug 6, 2024 | Q2 2024 | -$3.36Est: -$11.36 | +70.4% | $1.1MEst: $680.0K | +62.4% | 10-Q |
| May 9, 2024 | Q1 2024 | -$13.92Est: -$11.20 | -24.3% | $582.0KEst: $460.0K | +26.5% | 10-Q |
| Mar 12, 2024 | Q4 2023 | -$12.16Est: -$14.56 | +16.5% | $376.0KEst: $710.0K | -47.0% | 10-K |
| Nov 14, 2023 | Q3 2023 | -$25.28Est: -$20.96 | -20.6% | $341.0KEst: $670.0K | -49.1% | — |
| Aug 14, 2023 | Q2 2023 | -$29.28Est: -$28.00 | -4.6% | $457.0KEst: $450.0K | +1.6% | 10-Q |
| May 8, 2023 | Q1 2023 | -$29.44Est: -$25.92 | -13.6% | $206.0KEst: $500.0K | -58.8% | — |